Table 1.
Trial Characteristics
| Characteristic | CSSC-004 | CCP-Argentina | CONV-ERT | C3PO | CoV-Early | Total |
|---|---|---|---|---|---|---|
| Control arm | Plasma | Saline | Saline | Saline/MVC | Plasma | … |
| Enrollment period | June 2020 to Oct 2021 |
June 2020 to Oct 2020 |
Nov 2020 to July 2021 |
Aug 2020 to Feb 2021 | Nov 2020 to July 2021 |
… |
| Trial duration, mo | 16 | 5 | 9 | 7 | 9 | 46 |
| Variants | 614G, Alpha, Beta, Delta | WA-1, D614G | D614G, Alpha | D614G | D614G, Alpha | … |
| Geography | US | Argentina | Spain | US | Netherlands | … |
| Target enrollment, No. | 1280 | 210 | 474 | 900 | 690 | 3554 |
| Enrolled, No. | 1225 | 160 | 376 | 511 | 421 | 2693 |
| mITT (% of target enrollment) | 1181 (92) | 154 (73) | 369 (78) | 500 (55) | 416 (60) | 2620 (74) |
| Age, y, median (range) | 43 (18–85) | 77 (65 to ≥90) | 56 (IQR, 52–62) | 54 (18–93) | 60 (IQR, 55–65) | … |
| ≥1 medical high-risk condition for COVID-19 progression | 470 (40) | 131 (82) | 278 (74) | 511 (100) | 416 (100) | 1806 (68.6) |
| Enrollment symptom duration for inclusion, d | 0–8 | 0–3 | 0–7 | 0–7 | 0–7 | 0–8 |
| Symptoms ≤5 d | 517 (44) | 154 (100) | 283 (77) | 389 (78) | 226 (54) | 1569 (60) |
| Symptoms ≤3 d | 168 (14) | 154 (100) | 101 (27) | 240 (48) | 52 (13) | 715 (27) |
| Median/mean duration of symptoms, median (mean) | 6 | 3 | (4.4) | 4 | 5 | … |
| Total female | 675 (57) | 98 (64) | 169 (46) | 265 (53) | 93 (22) | 1300 (50) |
| Age >50 y | 411 (35) | 154 (100) | 368 (100) | 310 (61) | 414 (100) | 1657 (63) |
| Age >65 y | 80 (7) | 154 (100) | 73 (20) | 95 (19) | 113 (27) | 515 (20) |
| Diabetes | 99 (8) | 35 (23) | 39 (10) | 142 (28) | 29 (7) | 344 (13) |
| Hypertension | 276 (23) | 110 (71) | 244 (66) | 216 (42) | Not reported | 846 (38)a |
| Obesity (BMI >30 kg/m2) | 444 (38) | 11 (7) | 95 (26) | 302 (60) | 126 (30) | 978 (37) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; C3PO, clinical-trial of COVID-19 convalescent plasma in outpatients; CCP-Argentina, COVID-19 convalescent plasma-Argentina; CONV-ERT, convalescent methylene blue treated (MBT) plasma for early treatment; CoV-Early, early convalescent plasma therapy; CSSC-004, COVID-19 serologic studies consortium; COVID-19, coronavirus disease 2019; IQR, interquartile range; mITT, modified intention-to-treat (those transfused); MVC, multivitamin concentrate; US, United States.
Only included 4 reported studies.